Drs Batts and Lazarus are to be congratulated on their excellent review of transplantation-associated thrombotic microangiopathy (TMA). 1 As they highlight, one of the major unresolved issues is diagnosis; it is hard to be certain we are all talking about the same medical problem. 2, 3 The two sets of diagnostic criteria have major problems. An elevated lactate dehydrogenase (LDH) is a cardinal feature of the syndrome. 2 What does 'sudden and persistent increase' in LDH mean? 'Increased LDH above institutional baseline' is equally vague. Common clinical experience is that LDH is elevated in most patients with sepsis or hepatic dysfunction, and it can be persistent. A recent survey of 10 in-patients having allografts in our unit (at varying times post transplant) showed that 4 had an elevated LDH but all were below twice normal. Making the criterion an LDH that is twice normal 1 (institutional values), as we reported, is far more useful; at least we can all agree what that means. All 22 patients in the Bristol series met that criterion. There is a risk of overdiagnosing this problem. In a similar vein, the International Working Group definition that includes a platelet count o5 Â 10 9 /l is not helpful. Depending on transfusion policies in patients with suspected post-transplant TMA (another controversy) most of us would not allow the platelet count to go that low.
Until we, as transplant physicians, agree about what we will and will not regard as TMA, there will be no progress. Even if we are relatively demanding in our definitions and select a severe subset of patients, what is the harm in that? This severe subset of patients could be the subject of laboratory investigations that hopefully will improve our understanding of the condition (and therefore lead to rational treatment) but also could be the group investigated with randomized controlled trials of the potentially active therapies that the authors described. At the beginning of 2008, it is true to say that there is no proven therapy for this problem and most of the studies of therapy are anecdotal at best. Prospective trials will require multicentre (and probably multinational) collaboration. Why do not we do them? Surely that is the reason why groups such as the US BMT Clinical Trials Network and the European BMT group were formed.
To return to the opening sentence of the review; TMA is not in our experience 'infrequent' and it is far worse than 'frustrating'. It deprives a significant number of transplant patients of the opportunity to be cured. Some patients with TMA would die of other complications but many would otherwise survive.
DI Marks 1 and JM Bird

